AFT Pharmaceuticals gets approval to crack US market
AFT Pharmaceuticals has secured access to the multibillion-dollar United States painkiller market, with approval of its rapid-release Maxigesic tablets.In an update to the New Zealand stock exchange on Thursday, the company announced the Food and Drug Administration (FDA), a regulator, had approved the use of Maxigesic Rapid for the management of mild to moderate acute pain in the US.Maxigesic Rapid, taken in tablet form, is a combination of paracetamol and ibuprofen deployed via a patented rapid-release technology.The US analgesic or painkille...
Subscribe to BusinessDesk
Stay informed on business, government and financial developments across New Zealand.
- Stay informed on business, government and financial developments across New Zealand.
- Deeply researched, twice-edited and fact-checked news
- Annual subscribers also receive a complimentary subscription to The Wall Street Journal
- Personalised email news alerts, plus gift up to 5 stories a month to non-subscribers
You can cancel anytime with two clicks, an email or a phone call.
Find out
more.
We are serious about journalism.
Or use the information you’ve already given Google to create your subscription.
Not convinced yet?
Subscribe to our free 7am Headlines newsletter.
A quick summary of everything BusinessDesk has published in the previous 24 hours. No BusinessDesk
subscription needed.